

---

# Index

## A

- Abdominal and thoracic situs, 180, 183
- Acquired heart disease, 5, 20, 112, 115, 203
- Acute cellular rejection (ACR), 193
- Acute chest syndrome (ACS), 231, 232
- Acute decompensated heart failure, 11
- Acute fulminant myocarditis, 203
- Acute pulmonary embolism
  - anticoagulation, 247
  - fibrinolytic agent, 247, 248
  - mechanisms of action, 247
  - risk factors, 247, 248
  - systemic fibrinolysis, 247
  - ultrasound accelerated fibrinolysis, 248
- Acute rheumatic fever (ARF)
  - arthritis, 318
  - carditis, 317
  - case analysis, 315
  - chorea, 318
  - complications, 322
  - differential diagnosis, 319
  - erythema marginatum, 319
  - Jones criteria, 316, 317
  - laboratory evidence, 319
  - minor criteria, 319
  - ongoing management, 320–322
  - pathophysiology, 316
  - primary and secondary prophylaxis, 320, 321
  - risk stratification, 316
  - subcutaneous nodules, 319
- Acute shunt thrombosis, 43
- Acyanotic congenital heart defects, 95
- Age-specific lesions, 5
- Albumin, 120, 342
- Allograft rejection
  - acute cellular rejection, 193
  - adverse effects, 191–192
  - antibody-mediated rejection, 193
  - case analysis, 190
  - complications, 194
  - immunosuppressive therapy, 192
  - laboratory studies, 191–192
  - management, 194
  - mechanical circulatory support, 194
  - signs and symptoms, 190
- Anomalous origin of left coronary artery from pulmonary artery (ALCAPA), 4
- Antiarrhythmics
  - adenosine, 127
  - amiodarone, 128
  - epinephrine, 126
  - esmolol, 127
  - isoproterenol, 128
  - lidocaine, 128
  - magnesium sulfate, 128
- Antibody-mediated rejection (AMR), 193
- Anticoagulation, 247
- Antidromic AVRT, 149
- Antihypertensives, 125
- Antimicrobial prophylaxis, 197
- Antiviral prophylaxis, 197
- Aortic arch obstruction, 44
- Aortic stenosis, 380
- Aortic valvuloplasty, 245
- Arrhythmias, 117, 132, 376
- Arterial oxygen carrying capacity, 273, 275, 276
- Arterial oxygen content, 269
- Artifact/lead misplacement, 139
- Atrial arrhythmia, 80, 81
- Atrial ectopic tachycardia (AET), 143
- Atrial fibrillation, 146, 150
- Atrial septal defect (ASD), 95, 96, 235
- Atrial septectomy, 44
- Atrial tachycardia, 80

- Atrioventricular node (AVN)  
 AVNRT, 146, 147  
 conduction, 151, 152  
 re-entry pathway, 140
- Atrioventricular reciprocating tachycardia (AVRT), pre-excitation syndromes, 147, 150
- Atrioventricular septal defects (AVSDs), 95, 102, 103, 378
- Autoimmune disorders, 320
- Autonomic instability, 361–362
- AV node re-entrant tachycardia (AVNRT), 146, 147
- B**
- Balloon atrial septostomy (BAS), 238, 239
- Balloon valvuloplasty  
 aortic, 245  
 pulmonary, 246
- Berlin Heart EXCOR, 208, 210, 212, 215
- Beta-agonist therapy, 259
- Bidirectional Glenn/hemi-Fontan procedure, 90, 91
- Bidirectional ventricular tachycardia, 158
- Bimodal pattern, 203
- Blalock-Taussig shunt, 92
- Blood pressure, 272
- Bony abnormalities, 185, 186
- Bronchiolitis  
 airway obstruction, 258  
 beneficial effects, 260  
 beta-agonist therapy, 259  
 clinical diagnosis, 259  
 dynamic hyperinflation and auto-PEEP, 258  
 Glenn procedure, 259  
 HFNC therapy, 260  
 mechanical ventilation, 260  
 nebulized hypertonic saline therapy, 259  
 Norwood procedure, 258  
 symptoms and signs, 258  
 treatment, 259
- Bronchopulmonary dysplasia (BPD), 223–224
- $\beta_1$ -selective blocker, 126
- C**
- Calcium channel blockers, 125
- Cardiac action potential, 118
- Cardiac catheterization, 100
- Cardiac channelopathies, 157
- Cardiac conduction and rhythm generation, 117, 118
- Cardiac devices, 153
- Cardiac output, 269
- Cardiac standstill, FOCUS, 298
- Cardiac tamponade  
 signs, 236  
 typical findings, 236  
*See also* Pericardial tamponade
- Cardiac transplantation, 34
- Cardiogenic shock, 2  
 afterload reduction, 274  
 age of occurrence, 268  
 arterial oxygen carrying capacity, 275, 276  
 arterial oxygen content, 269  
 atrioventricular synchrony, 274–275  
 cardiac output, 269, 270  
 causes, 268  
 contractility, 274  
 diagnosis  
 blood pressure, 272  
 disproportionate tachycardia, 271  
 pulse pressure, 272  
 wheezing, 272, 273  
 ductal-dependent systemic blood flow  
 lesions, 277–278  
 fluid therapy response, 273  
 myocardia of neonates vs. children, 270  
 oxygen consumption, 269  
 oxygen delivery, 273  
 oxygen demand, 268, 273  
 pericardial tamponade  
 causes, 280  
 clinical findings, 280–281  
 fibrous layer, 279  
 hyperdynamic heart and scalloping, 281  
 laboratory findings, 281  
 parietal and visceral layers, 279  
 pericardial effusion, 282  
 serous layer, 279  
 stages, 279  
 swinging heart, 281  
 treatment, 283  
 water bottle-shaped heart, 281  
 preload optimization, 274  
 signs, 271  
 symptoms, 271
- Cardiomegaly, 8, 9, 12
- Cardiopulmonary interactions  
 acid-base balance, 257  
 afterload, 256

- arterial blood gases, 257
  - extrathoracic airway obstruction, 256
  - functional residual capacity, 256
  - intrathoracic airway obstruction, 256
  - intrathoracic pressure changes, 254
  - MSVP, 257
  - pathophysiologic changes, 254
  - pericardial effusion, 256
  - preload, 256
  - pulmonary and systemic circulations, 255, 256
  - Cardiothoracic ratio, 170
  - Catheter-based therapy, 247
  - CentriMag/PediMag, 212
  - Chest pain
    - focused physical examination, 371
    - history, 371
    - management, 372
    - non-cardiac
      - gastrointestinal, 370
      - musculoskeletal, 370
      - psychogenic, 370
      - respiratory, 370
    - patient follow-up, 372–373
    - symptoms, 369
    - testing, 371–372
  - Chronic thromboembolic pulmonary hypertension (CTEPH)
    - airway patency, 228
    - arbitrary hematocrit, 227
    - breathing, 228
    - circulation, 228
    - clinical presentation, 226–229
    - heparin, 229
    - laboratory evaluation, 225
    - multiple bilateral subsegmental filling defects, 225
    - polycythemia, 227
    - pulmonary thromboembolic disease, 227
    - PVOD, 227
    - risk factors, 226, 227
    - small airway disease, 225
    - symptoms, 225
    - vital signs, 225
    - warfarin, 229
  - Coagulase-negative *Staphylococcus* (CONS), 305
  - Coarctation of aorta, 7, 36, 185, 186, 271, 274, 296, 380
  - Colloids, 120–121
  - Complete heart block, 152, 154, 242, 358, 364–367
  - Congenital heart defects (CHD), *see* Congenital heart disease
  - Congenital heart disease, 81, 131, 304, 337
    - acute management, 11
    - birth defect, 83
    - cardiac emergencies, 1
    - congenital malformations, 1
    - fluid administration, 11
    - prevalence, 1
    - primary care setting, 83
    - pulmonary vasodilator, 11
    - surgical repair, 83
  - Congestive heart failure, 100
    - drugs, 105
  - Conventional heart failure therapy, 365
  - Coronary hypoperfusion, 39
  - Critical congenital heart disease (CCHD), 1
  - Croup, 260–261
  - Cyanosis, 263
- D**
- Decompensated heart failure, 121
  - Dengue myocarditis, 356
  - Dextrocardia, 137, 138
  - Diabetic ketoacidosis, 134
  - Dilated cardiomyopathy (DCM), 207
    - calcium/vitamin D deficiency, 344
    - case analysis, 341
    - clinical manifestations, 342
    - emergency stabilization, 343–344
    - etiology, 341
    - laboratory investigations, 342, 343
    - pathophysiology, 341
  - Diphtheria
    - case analysis, 362
    - clinical manifestations, 363
    - conduction blocks/complete heart block, 364–367
    - diphtheritic myocarditis, 365–367
    - emergency management principles, 364–365
    - etiology, 362
    - laboratory investigations, 364
    - pathophysiology, 363
    - ventricular tachycardias, 364
  - Diphtheritic myocarditis, 365–367
  - Disproportionate tachycardia, 271
  - Diuretic therapy, 121, 122
  - Dual-chamber pacemaker function, 154
  - Ductal-dependent cardiac disease, 7
  - Ductal-dependent lesions, 6, 9

- Ductal-dependent systemic blood flow lesions, 277, 278
- Ductus arteriosus, 277, 278  
congenital heart lesions, 117
- E**
- Early repolarization, 136
- Echocardiography  
balloon atrial septostomy, 239  
intermittent premature ventricular contractions, 240  
location, size and hemodynamic effect, 236
- Ectopic atrial tachycardia (EAT), 143
- Eisenmenger syndrome, 97
- Electrocardiography  
low QRS voltage and electrical alternans, 236  
syncope, 375–376
- Electrolyte imbalance, 135
- Endomyocardial biopsy, 191
- Erythema marginatum, 319
- Extracorporeal CPR (ECPR), 250
- Extracorporeal membrane oxygenation (ECMO), 194  
absolute contraindications, 205  
advantage, 205  
cannulation, 204, 249, 250  
case analysis, 202  
complications, 206  
definition, 204  
epidemiology, 202–203  
laboratory and electrocardiographic findings, 203  
management, 203–204  
outcomes, 206–207  
signs, 203  
symptoms, 203
- F**
- Fenestration, 54, 63, 65, 90
- Focused cardiovascular ultrasound (FOCUS)  
apical view, 289, 291  
clinical applications  
cardiac standstill, 298  
fluid resuscitation, 299  
hydration, 299  
inferior vena cava volume  
collapsibility, 299  
pericardial effusion, 292–296  
shock, 293–298  
high-frequency probe, 286  
limitations, 299, 300  
lower-frequency probe, 286  
motion-mode/M-mode echocardiography, 290–292  
parasternal long-axis view, 288, 289  
parasternal short-axis view, 289, 290  
phased-array probes, 286  
subxiphoid/subcostal view, 287, 288  
transducer footprint, 286
- Fontan procedure, 90, 92, 93, 264  
differential diagnosis, 80  
echocardiogram, 65  
Gore-Tex® tube, 56  
with intra-atrial reentrant tachycardia, 79  
and respiratory syncytial virus, 75  
symptoms, 81
- Foreign body retrieval, 240
- Functionally univentricular heart  
bidirectional superior cavopulmonary connection, 53  
completion Fontan procedure, 53  
evaluation of, 57  
hemi-Fontan procedure, 53  
hemodynamic assessment, 81  
management, 86  
physiology, 51, 80  
pulmonary artery band, 53  
pulmonary circulation, 52  
with right heart hypoplasia  
anemia, 66  
arterial blood gas, 66  
breath/tachypnea, 58  
chest X-ray, 59, 61  
clinical presentation, 77  
color changes, 57  
cyanosis, 60  
differential diagnosis, 67  
ECG, 60, 61  
echocardiography after completion  
Fontan circuit, 65  
echocardiography after palliation, 62  
echocardiography after superior cavopulmonary connection, 64  
electrolyte disturbances, 66  
feeding history, 58  
fever/illnesses, 58  
Fontan circulation, 66  
heart rate/tachycardia, 58  
hepatomegaly, 60  
irritability/increased fussiness, 58  
lethargy/easy fatigue, 58  
loss of consciousness, 58  
lung auscultation, 59  
myocardial dysfunction, 59  
PEEP levels, 77

- peripheral perfusion, extremities, 60
  - tricuspid/pulmonary atresia, 59
  - ventilatory management, 77
  - vital signs, 58
  - white blood cell count, 66
  - single-ventricle lesions, 84
  - surgical interventions, 84
  - systemic-to-pulmonary shunt, 53
  - total cavopulmonary connection, 53
  - venous blood flow, 53
  - Functional residual capacity (FRC), 94, 256, 257
- G**
- Gastroenteritis, 17, 48, 260–264
  - Genetic cardiac channelopathies, 157
  - Glenn procedure, 90, 93
- H**
- Heart disease
    - age, 5
    - albuterol administration, 6
    - early infancy, 4
    - early neonatal hemodynamic adaptation, 3
    - ED management, 2, 12, 13
    - historical findings, 6, 7
    - oxygen administration, 6
    - treatment strategies, 6
  - Heart failure (HF)
    - acute care settings, 18, 29
    - blood pressure, 28
    - cardiac output, 28
    - cardiomegaly, 23
    - causes, 20
    - chest radiograph, 23, 24
    - classification systems, 19
    - clinical characteristics, 18, 21
    - developmental characteristics, 18
    - diagnostic classifications, 18, 22
    - diastolic dysfunction, 18
    - diuretics, 28
    - echocardiographic abnormalities, 26, 27
    - ejection fraction, 18
    - electrocardiogram, 23
    - in emergency department, 30
    - exercise testing, 18
    - fluid management, 29
    - history, 22
    - impaired cardiac output, 22
    - inotropic agents, 29
    - intravenous/intraosseous access, 28
    - laboratory tests, 26
    - 15-lead electrocardiogram, 24
    - management algorithm, 21, 29, 30
    - mechanical circulatory support, 29
    - mechanisms, 21
    - milrinone, 29
    - myocardial pump function failure, 21
    - noninvasive imaging modalities, 25
    - physical examination, 22, 23
    - preserved EF, 18
    - renin-angiotensin-aldosterone system
      - blockade, 21
    - risk classification, 18
    - staging criteria, 18
    - symptoms/signs, 18
    - systemic/pulmonary venous congestion, 22
    - systolic dysfunction, 18
    - TandemHeart, 29
    - tissue oxygen delivery, 21
    - tracheal intubation and mechanical ventilation, 28
    - treatment, 18
    - venoarterial extracorporeal membrane oxygenation, 29
    - venous congestion, 22
    - vital signs, 23
  - Heart transplant
    - cardiomyopathy refractory, 189
    - ER physician, 190
    - history, 189
    - infection
      - antimicrobial prophylaxis, 197
      - antiviral prophylaxis, 197
      - case analysis, 194
      - chronic viral infections, 198
      - CNS infections, 198
      - differential diagnosis, 195–197
      - nystatin, 198
      - pre-transplant factors, 195
      - recurrence, 198
      - signs and symptoms, 195
      - transplant period, 196, 197
      - trimethoprim-sulfamethoxazole, 197
    - rejection
      - acute cellular rejection, 193
      - adverse effects, 191–192
      - antibody-mediated rejection, 193, 194
      - case analysis, 190
      - complications, 194
      - immunosuppressive therapy, 192
      - laboratory studies, 191–192
      - management, 194
      - mechanical circulatory support, 194
      - signs and symptoms, 190
    - survival rate, 189

- HeartMate II, 207, 210, 212, 215
- HeartWare, 209, 210, 212, 215
- Heterotaxy syndrome, 183
- High-flow nasal cannula (HFNC) therapy, 260
- High-frequency probe, 286
- HIV/AIDS
  - clinical manifestations, 358, 359
  - emergency management principles, 359–360
  - etiology, 357
  - laboratory investigations, 358
  - pathophysiology, 357
- Hormonal control over vascular tone, 115
- Hybrid palliation, 86
- Hypercalcemia, 136
- Hypercapnia with acidosis, 77
- Hypercyanotic spells
  - alpha-adrenergic stimulation, 166
  - blood flow, 162
  - clinical features, 165, 166, 168
  - congenital heart defects, 163
  - large ventricular septal defect, 164
  - local TPA infiltration, 167
  - management, 165
  - modified Blalock-Taussig shunt, 166, 167
  - oxygen saturation, 167
  - palliative modified Blalock-Taussig shunt placement, 166
  - paroxysmal hypoxic event, 162
  - pathophysiology, 162
  - post-balloon mBT shunt angioplasty, 167
  - sedation with morphine, 165
  - symptoms, 161
  - systemic vascular resistance, 162
  - tetralogy of Fallot, 163
- Hyperkalemia, 134
- Hypertrophic cardiomyopathy, 375
- Hypoplastic left heart syndrome (HLHS), 39, 40, 262, 263
  - acid-base imbalance, 48
  - anatomical subtypes, 34
  - anatomical variants, 34
  - antenatal detection of congenital heart disease, 33
  - antenatal ultrasound, 36
  - and aortic valve abnormalities, 34
  - arterial oxygen saturation, 35, 36, 39
  - atrial septal defect, 36
  - benign illnesses, 48
  - blood flow, 34
  - blood transfusion, 38
  - cardiac output, 37, 39, 42
  - circulatory collapse, 84
  - congenital cardiovascular malformations, 34
  - dehydration and hypovolemia, 48
  - diagnostic evaluation and management, 37
  - ductus arteriosus, 36
  - embryological origins, 34
  - etiology, 33
  - extracorporeal life support, 36
  - fetal blood, 34
  - genetic factors, 34
  - hybrid procedure, 39, 41, 45
  - hypotension, 48
  - incidence, 33
  - interatrial communication, 41
  - interstage period, 42
  - intravenous fluid resuscitation, 48
  - intravenous volume expansion, 38
  - management, 33
  - metabolic acidosis, 36, 84
  - Norwood procedure
    - with modified Blalock-Taussig shunt, 39
    - with Sano modification, 39, 40
  - obstruction severity, 34
  - oxygen therapy, 36
  - patent ductus arteriosus, 39
  - pathophysiology, 34
  - prenatal diagnosis, 84
  - pulmonary and systemic circulations, 35
  - pulmonary blood flow, 38, 39
  - pulmonary vascular resistance, 38
  - severity, 34
  - stage 2 and 3 palliations, 48
  - stage I palliation, 87, 90
  - stenosis/atresia, 34
  - supplemental oxygen, 37
  - symptoms, 36
  - systemic hypoperfusion, 38, 84
  - three-staged surgery, 39
  - volume resuscitation, 48
- Hypoplastic right heart syndrome (HRHS), 62, 72
  - ductal patency, 84, 91–93
- Hypovolemic shock, 276, 277
- Hypoxemia, 263
- Hypoxia, 163, 168, 263
- I**
- Impella, 212, 213, 250
- Inborn errors of metabolism, 277
- Independent circuits, 4

- Infection
- antimicrobial prophylaxis, 197
  - antiviral prophylaxis, 197
  - case analysis, 194
  - chronic viral infections, 198
  - CNS infections, 198
  - differential diagnosis, 195–197
  - nystatin, 198
  - pre-transplant factors, 195
  - recurrence, 198
  - signs and symptoms, 195
  - transplant period, 196, 197
- Infective endocarditis (IE), 380
- AACEK organisms, 305
  - Candida* species, 305
  - case analysis, 303–304, 348
  - coagulase-negative *Staphylococcus*, 305
  - complications, 311
  - culture-negative endocarditis, 306
  - echocardiographic changes, 307–308
  - emergency management principles, 350–351
  - epidemiology, 304
  - etiology, 349
  - focal neurologic deficit, 308
  - initial assessment and evaluation, 310
  - laboratory tests, 307, 350
  - modified Duke criteria, 307–309
  - outcomes, 312
  - pathophysiology, 304, 305, 349
  - physical signs, 306
  - preventing, 312
  - S. aureus*, 305
  - skin manifestations, 349
  - subacute presentation, 306
  - surgical evaluation, 311
  - treatment, 310
  - Viridans group *Streptococcus*, 305
- Inferior vena cava volume collapsibility, 299
- Inflammatory heart diseases
- Kawasaki disease
    - bilateral, 323
    - case analysis, 322
    - clinical features, 324
    - complications, 328–329
    - conjunctival injection, 325
    - differential diagnosis, 326–327
    - evaluation, 325
    - extremity changes, 326
    - hemodynamics, 327
    - mucosal changes, 325
    - noncardiac features, 326
    - non-suppurative, 323
    - ongoing management, 327–328
    - pathophysiology, 323
    - shock, 327
  - myocarditis
    - acute myocarditis, 331
    - antiarrhythmic medications, 334
    - cardiac imaging, 333
    - case analysis, 329
    - chest pain, 331
    - complications, 335
    - differential diagnosis, 333
    - dobutamine, 333
    - fulminant myocarditis, 331
    - laboratory results, 332
    - mechanical circulatory support, 334
    - milrinone, 333
    - ongoing management, 334
    - pathophysiology, 330
    - respiratory support, 334
    - sudden cardiac death, 332
    - tests, 332
  - rheumatic fever
    - arthritis, 318
    - case analysis, 315
    - chorea, 318
    - complications, 322
    - differential diagnosis, 319
    - erythema marginatum, 319
    - Jones criteria, 316, 317
    - laboratory evidence, 319
    - minor criteria, 319
    - ongoing management, 320–322
    - pathophysiology, 316
    - primary and secondary prophylaxis, 320, 321
    - risk stratification, 316
    - subcutaneous nodules, 319
- Inotropy
- adrenergic agents, 122, 123
  - calcium sensitizers, 124
  - drugs, 123
  - phosphodiesterase inhibitors, 123
  - vasoactive agents, 104
- Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), 212, 214
- Intra-aortic balloon pump, 212, 213
- Intra-atrial reentrant tachycardia (IART), 61
- Intravascular and surgical devices, 186
- Intraventricular conduction delay (IVCD), 155, 156

**K**

- Kawasaki disease (KD)
  - bilateral, 323
  - case analysis, 322
  - clinical features, 324
  - complications, 328, 329
  - conjunctival injection, 325
  - differential Diagnosis, 326–327
  - evaluation, 323, 325
  - extremity changes, 326
  - hemodynamic, 327
  - mucosal changes, 325
  - noncardiac features, 326
  - non-suppurative, 323
  - ongoing management, 327–328
  - pathophysiology, 323
  - shock, 327

**L**

- Large shunts
  - case analysis, 339
  - clinical manifestations, 340
  - emergency management principles, 341
  - laboratory investigations, 340
  - pathophysiology, 339
- Laryngotracheobronchitis, *see* Croup
- Left bundle branch block (LBBB), 155, 156
- Left lung atelectasis, 9
- Left-sided obstructive lesions, 3
- Left-to-right shunt, 4
  - catecholamines, 104
  - clinical presentation, 100
  - diuretics, 105
  - dobutamine, 104
  - dopamine, 104
  - epinephrine, 104
  - fluid resuscitation, 103
  - furosemide, 105
  - indiscriminate oxygen therapy, 104
  - milrinone, 104
  - nitroglycerin, 105
  - nitroprusside, 105
  - pulmonary blood flow, 96
  - pulmonary over-circulation, 96
  - symptoms, 103
- Lower-frequency probe, 286

**M**

- Mean systemic venous pressure (MSVP), 257, 262
- Mechanical circulatory support
  - ECMO
    - absolute contraindications, 205

- advantages, 205
- cannulation, 204, 249, 250
- case analysis, 202
- complications, 206
- definition, 204
- epidemiology, 202–203
- laboratory and electrocardiographic findings, 203
- management, 203–204
- outcomes, 206–207
- signs, 203
- symptoms, 203

**VAD**

- Berlin Heart EXCOR, 210
  - case analysis, 207
  - complications, 215
  - durable devices, 212
  - epidemiology, 207
  - features, 208, 209
  - HeartMate II, 210
  - Impella, 212, 213
  - INTERMACS profiles, 212, 214
  - intra-aortic balloon pump, 212, 213
  - management, 208
  - outcomes, 215–217
  - patient populations, 215
  - PediMag/CentriMag, 212, 213
  - signs and symptoms, 208
  - TandemHeart, 212, 213
  - temporary devices, 209
  - total artificial heart, 212, 214

Metabolic acidosis, 224

Modified Blalock-Taussig shunt (mBTS), 52, 243, 244

- anemia, 73
- differential diagnosis, 72
- pulmonary process, 73
- shunt stenosis/occlusion, 72
- vascular resistance, 73

Modified Duke Criteria, 307–308

Monomorphic ventricular tachycardia, 126

Multiple transducers, 286

Murmur

- case analysis, 377
- history, 378, 379
- patient follow-up, 380–381
- physical examination, 379, 380

Myocardial depressants, 13

Myocardial injury, 156

Myocardial ischemia, 57

Myocarditis, 25, 202, 375

- acute myocarditis, 331
- antiarrhythmic medications, 334
- cardiac imaging, 333
- case analysis, 329, 354



- chest pain, 331
  - clinical manifestations, 355
  - complications, 335
  - differential diagnosis, 333
  - dobutamine, 333
  - emergency management principles, 356–357
  - etiology, 354
  - fulminant myocarditis, 331
  - laboratory investigations, 332, 355
  - mechanical circulatory support, 334
  - milrinone, 333
  - neonates vs. children, 270
  - ongoing management, 334
  - pathophysiology, 330, 355
  - respiratory support, 334
  - sudden cardiac death, 332
  - tests, 332
- N**
- Nebulized hypertonic saline therapy, 259
  - Neonatal and infantile cardiopulmonary adaptation, 2
  - Neurocardiogenic syncope, *see* Vasovagal syncope
  - Neurogenic shock, 277
  - Non-cardiac chest pain
    - gastrointestinal, 370
    - musculoskeletal, 370
    - psychogenic, 370
    - respiratory, 370
  - Noncardiogenic (septic) shock, 180
  - Noninvasive positive pressure (NIPPV), 12
  - Normal biventricular circulation, 88
  - Norwood procedure, 85
- O**
- Osseous abnormalities, 185
  - Ostium Secundum ASD, 101, 102
  - Oxygen consumption, 269
  - Oxygen delivery, 269, 273
  - Oxygen demand, 268, 273
  - Oxygen supplementation, 264
- P**
- Pacemaker action potential, 119
  - Pacemakers and defibrillators, 153, 154
  - Packed red blood cells (PRBCs), 121
  - Patent ductus arteriosus (PDA), 35, 37, 103, 339
  - PediMag/CentriMag, 213
  - Pericardial drain placement, 237, 238
  - Pericardial effusion, 236, 238
    - FOCUS, 292–296
  - Pericardial tamponade
    - causes, 280
    - clinical findings, 281
    - fibrous layer, 279
  - HIV/AIDS
    - clinical manifestations, 358
    - emergency management principles, 359–360
    - etiology, 357
    - laboratory investigations, 358
    - pathophysiology, 357
  - laboratory findings, 281
  - parietal and visceral layers, 279
  - pericardial effusion, 282
  - serous layer, 279
  - stages, 279
  - swinging heart, 281
  - treatment, 283
  - water bottle-shaped heart, 281
- Pericardiocentesis, 235–238, 359
- Pericarditis, 375
- Peripheral epinephrine, 265
- Pharmacology
- adrenergic receptors, 116
  - afterload, 114, 116
  - angiotensin II, 115
  - ductal patency, 117
  - inotropy, 112, 113
    - adrenergic agents, 122, 123
    - calcium sensitizers, 124
    - dobutamine, 122
    - dopamine, 122
    - epinephrine, 123
    - isoproterenol, 123
    - norepinephrine, 123
    - phosphodiesterase inhibitors, 123
  - length-tension relationship, 111
  - optimal preload, 110–112, 119
  - optimum cardiovascular function, 110
  - physiologic differences, 116
  - preload, 111
    - volume expansion, 120
- Phased-array probes, 286
- Pleural effusions, 76
- Pneumonia, 137
- Polycythemia, 227
- Positive end-expiratory pressure (PEEP), 99, 104
- Positive pressure ventilation (PPV), 13
- Postcardiotomy syndromes, 280
- Post-pericardiotomy syndrome, 71, 236
- Premature atrial complexes (PAC), 133, 134
- Premature ventricular contractions (PVC), 158

Primary atrial rhythms, 142  
 Primary atrial tachycardia, 144, 145  
 Progressive cyanosis, 78  
 Pulmonary arterial circulation, 53  
 Pulmonary artery anastomosis, 64  
 Pulmonary artery banding, 53, 91  
 Pulmonary artery hypertension  
   cardiomegaly and diffuse pulmonary  
   congestion, 220  
   dilated left atrium and ventricle, 220  
   emergency management principles, 221  
   left ventricular/biventricular hypertrophy,  
   220  
   PVR, 220  
   signs and symptoms, 220  
   ventricular septal defect, 220  
 Pulmonary atresia  
   directional Glenn/hemi-Fontan procedure,  
   57  
   ductus arteriosus, 57  
   with intact ventricular septum, 54, 57  
     ductal dependant pulmonary  
     circulation, 73  
     ECG, 61  
 Pulmonary blood flow, 97  
 Pulmonary circulation, 85, 99  
 Pulmonary edema, 8, 12, 97  
 Pulmonary embolism, 227, 376  
 Pulmonary hypertension (PH), 76, 220, 226,  
   230  
   BPD, 223, 224  
   CTEPH (*see* Chronic thromboembolic  
     pulmonary hypertension (CTEPH))  
   left heart disease, 221–223  
   lung diseases and/or hypoxemia, 223  
   pulmonary artery hypertension (*see*  
     Pulmonary artery hypertension)  
   SCD (*see* Sickle cell disease (SCD))  
 Pulmonary overcirculation, 36, 46  
 Pulmonary sling, 177, 179, 183  
 Pulmonary stenosis, 380  
 Pulmonary thromboendarterectomy (PTE),  
   229  
 Pulmonary valvuloplasty, 246  
 Pulmonary vascularity, 96  
 Pulmonary vascular resistance (PVR), 3, 10,  
   76, 85, 87, 96, 115, 220  
 Pulmonary veno-occlusive disease (PVOD),  
   227  
 Pulmonary venous obstruction, 4  
 Pulse pressure, 272  
 Pulsus paradoxus (PP), 256

## Q

Qp:Qs ratio, 35, 38, 87–89, 97–100

## R

Radiographic evaluation, pediatric heart  
   disease  
     anterior tracheal line, 170  
     atrial septal defect, 187  
     cardiomediastinal silhouette, 176  
     cardiothoracic ratio, 170  
     chamber enlargement, 170  
     diagnosis, 169  
     differential diagnosis, 174, 177  
     distal trachea, 181  
     Ebstein's anomaly, tricuspid valve, 171  
     heart size and shape evaluation, 170, 171  
     heterotaxy, 184  
     hypertension, 185  
     mediastinum and airway, 177, 179  
     patent ductus arteriosus, 187  
     pulmonary vasculature, 174, 175  
     supracardiac total anomalous pulmonary  
     venous return, 171  
     systematic search pattern, 169  
     tetralogy of Fallot, 171, 177  
 Reactive pericarditis from chemotherapy, 71  
 Reflex syncope, *see* Vasovagal syncope  
 Repaired congenital heart disease, 155  
 Respiratory and metabolic acidosis, 104  
 Respiratory distress and cyanosis, 95, 179  
 Respiratory tract infections, 48  
 Restrictive atrial septal defect, 44, 45  
 Rheumatic carditis, 304, 380  
 Rhythm determination, heart, 117, 118  
 Right bundle branch block (RBBB) pattern,  
   155, 156, 158  
 Right modified Blalock-Taussig Shunt  
   (RMBTS), 63, 244  
 Right-sided obstructive heart lesions, 3  
 Right ventricular outflow tract (RVOT), 3, 158,  
   159, 162, 246  
 Ross classification for heart failure, 19  
 Rotaflow, 212

## S

Septic shock, 276, 277  
 Severe decompensated heart failure, 104  
 Shock, 267  
   cardiogenic (*see* Cardiogenic shock)  
   differential diagnosis, 276  
   FOCUS, 293–298  
   mechanism, 267  
   treating shock, 277  
 Shunt stenosis/occlusion, 74  
 Shunt thrombosis, catheter-based  
   treatment, 73  
 Sickle cell disease (SCD)  
   acute chest syndrome, 231

airway patency, 231  
 anemia, 231  
 breathing, 232  
 circulation, 232  
 clinical presentation, 230  
 hemolysis, 231  
 mild steady-state pulmonary hypertension,  
 231  
 moderate pulmonary artery pressure  
 elevation, 231  
 vaso-occlusive painful crisis, 231  
 Single-ventricle lesion with PVR, 89  
 Sinus arrhythmia, 132, 133  
 Sinus bradycardia, 142  
 Sinus node impulse, 142  
 Sinus rhythm, 159  
   with PAC, 134  
 Sinus tachycardia, 142  
 Situs solitus, 183  
 Still's murmur, 380  
 Stroke  
   case analysis, 344  
   clinical manifestations, 346  
   diagnosis, 348  
   emergency management, 347–348  
   etiology, 344  
   laboratory investigations, 345–346  
   pathophysiology, 345  
 Sudden unexplained cardiac death, 47  
 Superior vena cava-pulmonary artery, 76  
 Supraventricular tachycardia (SVT), 140–142,  
 146, 147  
 Surgical pericardiectomy, 353  
 Surgical thrombectomy, 247  
 Syncope, 374–376  
   case analysis, 373  
   clinical features  
     echocardiogram, 376  
     electrocardiogram, 375–376  
     history, 374–375  
     laboratory tests, 375  
     physical examination, 375  
   definition, 374  
   management, 376  
   patient follow-up, 376–377  
   vasovagal, 374  
 Systemic arteriovenous fistula, 3  
 Systemic blood flow, 97, 98  
 Systemic circulation, 99  
 Systemic fibrinolysis, 247  
 Systemic vascular resistance (SVR), 3, 13

## T

Tachypnea, 173  
 TandemHeart, 212, 213

Tetanus  
   case analysis, 360  
   emergency management  
     principles, 360  
   etiology, 360  
   laboratory investigations, 360  
   management algorithm, 361–362  
   pathophysiology, 360  
 Tetanus immunoglobulin (TIG), 360  
 Thrombosed BT shunt, 263  
 Thrombus formation/anatomical obstruction,  
 76  
 Total anomalous pulmonary venous return  
 (TAPVR), 4  
 Total artificial heart, 212, 214  
 Transcatheter retrieval  
   embolized atrial septal defect occluder  
     device, 240, 241  
   embolized ventriculoatrial  
     shunt, 240, 241  
 Transducer footprint, 286  
 Transvenous pacing lead placement, 242  
 Tricuspid atresia, 51, 78  
   arterial blood gas, 69  
   CBC with differential, 68  
   CXR, 67, 68, 70  
   differential diagnosis, 69  
   ECG, normal sinus rhythm, 60  
   echocardiogram, 68  
   with great arteries, 52  
     and pulmonary atresia, 53  
   with minimal restriction to pulmonary  
     blood flow, 70  
   with worsening cyanosis, 68  
   pericardial effusion and infection, 71  
   pulmonary overcirculation, 71  
   pulmonary stenosis, 62  
   pulse oximetry, 71  
   respiratory distress, 75  
   surgical palliation, 52  
   transesophageal and transthoracic  
     echocardiography, 62, 63  
   type 1a with Blalock-Taussig shunt, 94  
   type 1c, pulmonary artery, 93  
   type I B, 75  
 Tricuspid regurgitant jet (TRJ), 230  
 Tuberculosis  
   case analysis, 351  
   clinical features, 351–352  
   emergency management principles,  
     353–354  
   etiology, 351  
   laboratory investigations, 352  
   pathophysiology, 351–352  
   surgical pericardiectomy, 353  
 Tuberculous pericarditis (TP), 351

**U**

- Ultrasound accelerated fibrinolysis, 248
- Uncompensated heart failure, 10
- Unimmunized child, 360–367
  - diphtheria
    - case analysis, 362
    - clinical manifestations, 363
    - conduction/complete heart block, 364–367
    - diphtheritic myocarditis, 365–367
    - emergency management principles, 364–365
    - etiology, 362
    - laboratory investigations, 364
    - pathophysiology, 363
    - ventricular tachycardias, 364
  - tetanus
    - case analysis, 360, 362
    - etiology, 360
    - laboratory investigations, 360
    - management algorithm, 361–362
    - pathophysiology, 360
- Unpalliated tricuspid atresia, 69

**V**

- Vascular autoregulation, 115
- Vascular ring detection, trachea, 177
- Vasoconstrictors, 98, 115, 124, 125, 257
- Vasodilators, 8, 11, 29, 37, 38, 104, 125
- Vasovagal syncope, 374
- Venodilators, 121
- Venous hum, 380
- Veno-venous collaterals, 75, 77

- Ventricular arrhythmias, 136, 154
- Ventricular assist device (VAD)
  - Berlin Heart EXCOR, 210
  - case analysis, 207
  - complications, 215
  - durable devices, 212
  - epidemiology, 207
  - features, 208, 209
  - HeartMate II, 210
  - Impella, 212, 213
  - INTERMACS profiles, 212, 214
  - intra-aortic balloon pump, 212, 213
  - management, 208
  - outcomes, 215–217
  - patient populations, 215
  - PediMag/CentriMag, 212, 213
  - signs and symptoms, 208
  - TandemHeart, 212, 213
  - temporary devices, 209
  - total artificial heart, 212, 214
- Ventricular premature contractions (PVCs), 138
- Ventricular septal defects (VSDs), 95, 100, 220, 241, 265
- Ventricular tachycardia, 158
- Viral upper respiratory tract infection, 76
- Viridans group *Streptococcus* (VGS), 305

**W**

- Wheezing, 272, 273
- Wolff-Parkinson-White syndrome (WPW), 140, 147
- Wound care, 360